aav cmv gfp vector Search Results


96
Vector Biolabs ad cmv cre gfp
Ad Cmv Cre Gfp, supplied by Vector Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/pmc08265010-59-39-40?v=Vector+Biolabs
Average 96 stars, based on 1 article reviews
ad cmv cre gfp - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

92
Addgene inc plasmids pprime cmv gfp ff3
Plasmids Pprime Cmv Gfp Ff3, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/pm38499720-75-6-14?v=Addgene+inc
Average 92 stars, based on 1 article reviews
plasmids pprime cmv gfp ff3 - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier

93
Addgene inc nicd cdna inserted vector
Nicd Cdna Inserted Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/pmc03744728-333-0-3?v=Addgene+inc
Average 93 stars, based on 1 article reviews
nicd cdna inserted vector - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

93
Addgene inc destination vector plenticmv gfp dest
Destination Vector Plenticmv Gfp Dest, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/bio_rxiv__2023__11__22__567682-179-13-18?v=Addgene+inc
Average 93 stars, based on 1 article reviews
destination vector plenticmv gfp dest - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

93
Addgene inc aav gfap gfp cre vector
Aav Gfap Gfp Cre Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/bio_rxiv__2022__12__01__518727-99-10-36?v=Addgene+inc
Average 93 stars, based on 1 article reviews
aav gfap gfp cre vector - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

97
Addgene inc hslc9a6 aav expression plasmid
<t>AAV9-CAG-hSLC9A6</t> AAV increased cerebellar NHE6 and CALB1 abundances determined by western blotting and decreased motor ataxia. (A-D) Mirroring findings with PHP.eB-L7-Slc9a6-GFP AAV, administration of AAV9-CAG-hSLC9A6 AAV at ~ 5 weeks of age minimally increased NHE6 expression (A, C), but this minimal increase led to proportionally greater increases in CALB1 expression (B, D). (E) AAV9-CAG-hSLC9A6 AAV administration at 5 weeks of age significantly improved motor ataxia at 14 weeks of age compared to 7 untreated shaker rats (5 administered a control AAV and 2 uninjected). (F) Rats treated with AAV9-CAG-hSLC9A6 trended towards a decrease in tremor at 14 weeks of age, albeit with substantial variability. Note that each data point is an individual rat, and all n-values for statistics are calculated as number of rats, not technical replicates.
Hslc9a6 Aav Expression Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/pmc13050144-157-2-8?v=Addgene+inc
Average 97 stars, based on 1 article reviews
hslc9a6 aav expression plasmid - by Bioz Stars, 2026-07
97/100 stars
  Buy from Supplier

95
Vector Biolabs cmv promoter
<t>AAV9-CAG-hSLC9A6</t> AAV increased cerebellar NHE6 and CALB1 abundances determined by western blotting and decreased motor ataxia. (A-D) Mirroring findings with PHP.eB-L7-Slc9a6-GFP AAV, administration of AAV9-CAG-hSLC9A6 AAV at ~ 5 weeks of age minimally increased NHE6 expression (A, C), but this minimal increase led to proportionally greater increases in CALB1 expression (B, D). (E) AAV9-CAG-hSLC9A6 AAV administration at 5 weeks of age significantly improved motor ataxia at 14 weeks of age compared to 7 untreated shaker rats (5 administered a control AAV and 2 uninjected). (F) Rats treated with AAV9-CAG-hSLC9A6 trended towards a decrease in tremor at 14 weeks of age, albeit with substantial variability. Note that each data point is an individual rat, and all n-values for statistics are calculated as number of rats, not technical replicates.
Cmv Promoter, supplied by Vector Biolabs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/pm31296795-43-16-18?v=Vector+Biolabs
Average 95 stars, based on 1 article reviews
cmv promoter - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

95
Vector Biolabs aav9 cmv m rpl3
<t>AAV9-CAG-hSLC9A6</t> AAV increased cerebellar NHE6 and CALB1 abundances determined by western blotting and decreased motor ataxia. (A-D) Mirroring findings with PHP.eB-L7-Slc9a6-GFP AAV, administration of AAV9-CAG-hSLC9A6 AAV at ~ 5 weeks of age minimally increased NHE6 expression (A, C), but this minimal increase led to proportionally greater increases in CALB1 expression (B, D). (E) AAV9-CAG-hSLC9A6 AAV administration at 5 weeks of age significantly improved motor ataxia at 14 weeks of age compared to 7 untreated shaker rats (5 administered a control AAV and 2 uninjected). (F) Rats treated with AAV9-CAG-hSLC9A6 trended towards a decrease in tremor at 14 weeks of age, albeit with substantial variability. Note that each data point is an individual rat, and all n-values for statistics are calculated as number of rats, not technical replicates.
Aav9 Cmv M Rpl3, supplied by Vector Biolabs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/pmc12240844-89-6-7?v=Vector+Biolabs
Average 95 stars, based on 1 article reviews
aav9 cmv m rpl3 - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

95
Addgene inc transfer vector plenti cmv mcs gfp sv puro
<t>AAV9-CAG-hSLC9A6</t> AAV increased cerebellar NHE6 and CALB1 abundances determined by western blotting and decreased motor ataxia. (A-D) Mirroring findings with PHP.eB-L7-Slc9a6-GFP AAV, administration of AAV9-CAG-hSLC9A6 AAV at ~ 5 weeks of age minimally increased NHE6 expression (A, C), but this minimal increase led to proportionally greater increases in CALB1 expression (B, D). (E) AAV9-CAG-hSLC9A6 AAV administration at 5 weeks of age significantly improved motor ataxia at 14 weeks of age compared to 7 untreated shaker rats (5 administered a control AAV and 2 uninjected). (F) Rats treated with AAV9-CAG-hSLC9A6 trended towards a decrease in tremor at 14 weeks of age, albeit with substantial variability. Note that each data point is an individual rat, and all n-values for statistics are calculated as number of rats, not technical replicates.
Transfer Vector Plenti Cmv Mcs Gfp Sv Puro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/pmc09413995-432-1-4?v=Addgene+inc
Average 95 stars, based on 1 article reviews
transfer vector plenti cmv mcs gfp sv puro - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

93
Addgene inc lentivial expression vector pcdh cmv mcs ef1a gfp
<t>AAV9-CAG-hSLC9A6</t> AAV increased cerebellar NHE6 and CALB1 abundances determined by western blotting and decreased motor ataxia. (A-D) Mirroring findings with PHP.eB-L7-Slc9a6-GFP AAV, administration of AAV9-CAG-hSLC9A6 AAV at ~ 5 weeks of age minimally increased NHE6 expression (A, C), but this minimal increase led to proportionally greater increases in CALB1 expression (B, D). (E) AAV9-CAG-hSLC9A6 AAV administration at 5 weeks of age significantly improved motor ataxia at 14 weeks of age compared to 7 untreated shaker rats (5 administered a control AAV and 2 uninjected). (F) Rats treated with AAV9-CAG-hSLC9A6 trended towards a decrease in tremor at 14 weeks of age, albeit with substantial variability. Note that each data point is an individual rat, and all n-values for statistics are calculated as number of rats, not technical replicates.
Lentivial Expression Vector Pcdh Cmv Mcs Ef1a Gfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/pmc10129859-70-1-6?v=Addgene+inc
Average 93 stars, based on 1 article reviews
lentivial expression vector pcdh cmv mcs ef1a gfp - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

90
Vector Biolabs spcas9
<t>AAV9-CAG-hSLC9A6</t> AAV increased cerebellar NHE6 and CALB1 abundances determined by western blotting and decreased motor ataxia. (A-D) Mirroring findings with PHP.eB-L7-Slc9a6-GFP AAV, administration of AAV9-CAG-hSLC9A6 AAV at ~ 5 weeks of age minimally increased NHE6 expression (A, C), but this minimal increase led to proportionally greater increases in CALB1 expression (B, D). (E) AAV9-CAG-hSLC9A6 AAV administration at 5 weeks of age significantly improved motor ataxia at 14 weeks of age compared to 7 untreated shaker rats (5 administered a control AAV and 2 uninjected). (F) Rats treated with AAV9-CAG-hSLC9A6 trended towards a decrease in tremor at 14 weeks of age, albeit with substantial variability. Note that each data point is an individual rat, and all n-values for statistics are calculated as number of rats, not technical replicates.
Spcas9, supplied by Vector Biolabs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/pm34257302-277-4-26?v=Vector+Biolabs
Average 90 stars, based on 1 article reviews
spcas9 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

93
Addgene inc aav vector aav flex arch gfp vector
<t>AAV9-CAG-hSLC9A6</t> AAV increased cerebellar NHE6 and CALB1 abundances determined by western blotting and decreased motor ataxia. (A-D) Mirroring findings with PHP.eB-L7-Slc9a6-GFP AAV, administration of AAV9-CAG-hSLC9A6 AAV at ~ 5 weeks of age minimally increased NHE6 expression (A, C), but this minimal increase led to proportionally greater increases in CALB1 expression (B, D). (E) AAV9-CAG-hSLC9A6 AAV administration at 5 weeks of age significantly improved motor ataxia at 14 weeks of age compared to 7 untreated shaker rats (5 administered a control AAV and 2 uninjected). (F) Rats treated with AAV9-CAG-hSLC9A6 trended towards a decrease in tremor at 14 weeks of age, albeit with substantial variability. Note that each data point is an individual rat, and all n-values for statistics are calculated as number of rats, not technical replicates.
Aav Vector Aav Flex Arch Gfp Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav+cmv+gfp+vector/pmc06605193-242-10-14?v=Addgene+inc
Average 93 stars, based on 1 article reviews
aav vector aav flex arch gfp vector - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

Image Search Results


AAV9-CAG-hSLC9A6 AAV increased cerebellar NHE6 and CALB1 abundances determined by western blotting and decreased motor ataxia. (A-D) Mirroring findings with PHP.eB-L7-Slc9a6-GFP AAV, administration of AAV9-CAG-hSLC9A6 AAV at ~ 5 weeks of age minimally increased NHE6 expression (A, C), but this minimal increase led to proportionally greater increases in CALB1 expression (B, D). (E) AAV9-CAG-hSLC9A6 AAV administration at 5 weeks of age significantly improved motor ataxia at 14 weeks of age compared to 7 untreated shaker rats (5 administered a control AAV and 2 uninjected). (F) Rats treated with AAV9-CAG-hSLC9A6 trended towards a decrease in tremor at 14 weeks of age, albeit with substantial variability. Note that each data point is an individual rat, and all n-values for statistics are calculated as number of rats, not technical replicates.

Journal: Human Molecular Genetics

Article Title: Viral vector-mediated SLC9A6 gene replacement reduces cerebellar motor and molecular abnormalities in the shaker rat model of Christianson syndrome

doi: 10.1093/hmg/ddag021

Figure Lengend Snippet: AAV9-CAG-hSLC9A6 AAV increased cerebellar NHE6 and CALB1 abundances determined by western blotting and decreased motor ataxia. (A-D) Mirroring findings with PHP.eB-L7-Slc9a6-GFP AAV, administration of AAV9-CAG-hSLC9A6 AAV at ~ 5 weeks of age minimally increased NHE6 expression (A, C), but this minimal increase led to proportionally greater increases in CALB1 expression (B, D). (E) AAV9-CAG-hSLC9A6 AAV administration at 5 weeks of age significantly improved motor ataxia at 14 weeks of age compared to 7 untreated shaker rats (5 administered a control AAV and 2 uninjected). (F) Rats treated with AAV9-CAG-hSLC9A6 trended towards a decrease in tremor at 14 weeks of age, albeit with substantial variability. Note that each data point is an individual rat, and all n-values for statistics are calculated as number of rats, not technical replicates.

Article Snippet: To generate hSLC9A6 AAV expression plasmid, pAAV-CAG-GFP plasmid (Addgene plasmid #37825, gifted from Edward Boyden) was modified by deleting GFP with BamHI and EcoRI restriction enzymes.

Techniques: Western Blot, Expressing, Control

Following AAV9-CAG-hSLC9A6 AAV administration, ataxia, NHE6, and CALB1, are interrelated, but NHE6 and CALB1 are not correlated with tremor at 14 weeks of age. (A) NHE6 abundance following viral administration of AAV9-CAG-hSLC9A6 AAV positively correlates with CALB1 expression, suggesting a rescue of Purkinje cells. (B) NHE6 abundance is likewise negatively correlated with gait ataxia. (C) CALB1 is highly negatively correlated with gait ataxia. (D-E) While NHE6 and CALB1 abundance were correlated with ataxia and ataxia is correlated with tremor, NHE6 and CALB1 are not significantly correlated with tremor. Grey shaded regions represents 95% confidence intervals.

Journal: Human Molecular Genetics

Article Title: Viral vector-mediated SLC9A6 gene replacement reduces cerebellar motor and molecular abnormalities in the shaker rat model of Christianson syndrome

doi: 10.1093/hmg/ddag021

Figure Lengend Snippet: Following AAV9-CAG-hSLC9A6 AAV administration, ataxia, NHE6, and CALB1, are interrelated, but NHE6 and CALB1 are not correlated with tremor at 14 weeks of age. (A) NHE6 abundance following viral administration of AAV9-CAG-hSLC9A6 AAV positively correlates with CALB1 expression, suggesting a rescue of Purkinje cells. (B) NHE6 abundance is likewise negatively correlated with gait ataxia. (C) CALB1 is highly negatively correlated with gait ataxia. (D-E) While NHE6 and CALB1 abundance were correlated with ataxia and ataxia is correlated with tremor, NHE6 and CALB1 are not significantly correlated with tremor. Grey shaded regions represents 95% confidence intervals.

Article Snippet: To generate hSLC9A6 AAV expression plasmid, pAAV-CAG-GFP plasmid (Addgene plasmid #37825, gifted from Edward Boyden) was modified by deleting GFP with BamHI and EcoRI restriction enzymes.

Techniques: Expressing

(A) In the context of AAV9-CAG-hSLC9A6 AAV experiments, ataxia is strongly correlated with tremor at 14 weeks. (B-C) In the context of PHP.eB-Slc9a6-GFP AAV experiments, the correlation between peak tremor and late-stage ataxia is stronger than the correlation between tremor and ataxia at any given timepoint. (B) Ataxia and tremor are initially strongly related following symptom onset, but this correlation significantly decreases over time. (C) Peak tremor occurred prior to 20 weeks in all but 2 animals; however, the correlation between peak ataxia and late-stage ataxia (21–25 weeks) was higher than the correlation between tremor and ataxia at any individual timepoint. (D) Endpoint NHE6 expression and ataxia were negatively correlated at all timepoints. This negative correlation became stronger over time. (E) NHE6 and tremor were negatively correlated at all timepoints; however, the correlation between NHE6 and tremor did not strengthen over time. Grey shaded regions represents 95% confidence intervals.

Journal: Human Molecular Genetics

Article Title: Viral vector-mediated SLC9A6 gene replacement reduces cerebellar motor and molecular abnormalities in the shaker rat model of Christianson syndrome

doi: 10.1093/hmg/ddag021

Figure Lengend Snippet: (A) In the context of AAV9-CAG-hSLC9A6 AAV experiments, ataxia is strongly correlated with tremor at 14 weeks. (B-C) In the context of PHP.eB-Slc9a6-GFP AAV experiments, the correlation between peak tremor and late-stage ataxia is stronger than the correlation between tremor and ataxia at any given timepoint. (B) Ataxia and tremor are initially strongly related following symptom onset, but this correlation significantly decreases over time. (C) Peak tremor occurred prior to 20 weeks in all but 2 animals; however, the correlation between peak ataxia and late-stage ataxia (21–25 weeks) was higher than the correlation between tremor and ataxia at any individual timepoint. (D) Endpoint NHE6 expression and ataxia were negatively correlated at all timepoints. This negative correlation became stronger over time. (E) NHE6 and tremor were negatively correlated at all timepoints; however, the correlation between NHE6 and tremor did not strengthen over time. Grey shaded regions represents 95% confidence intervals.

Article Snippet: To generate hSLC9A6 AAV expression plasmid, pAAV-CAG-GFP plasmid (Addgene plasmid #37825, gifted from Edward Boyden) was modified by deleting GFP with BamHI and EcoRI restriction enzymes.

Techniques: Expressing